5 Mighty Small-Cap Stocks to Buy for 2014

Small cap stocks outperform large in rising rate environments

      View All  
5 Mighty Small-Cap Stocks to Buy for 2014


Back in June, molecular diagnostics company Cepheid (CPHD) gained FDA approval for its updated Xpert MRSA/SA BC test (part of its popular GeneXpert system). The test detects infections in blood specific to causes of sepsis in hospitalized patients. The $2.7 billion company reported third-quarter 2013 revenues of $100.1 million, a 24% increase over the same quarter a year ago. Cepheid offers the most popular molecular diagnostic platform on the market; its stock has performed admirably, up 25% over the past six months.

Article printed from InvestorPlace Media, http://investorplace.com/2013/12/small-cap-stocks-to-buy-wen-hmn-rlgyfor-2014/.

©2015 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.